DDrare: Database of Drug Development for Rare Diseases

Mirdametinib (pd-0325901) oral capsule or dispersible tablet (DrugBank: PD-0325901)

告示番号	疾患名（ページ内リンク）	臨床試験数
34	神経線維腫症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03962543 (ClinicalTrials.gov)	September 6, 2019	12/4/2019	MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas	A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity	Plexiform Neurofibroma;Neurofibromatosis Type 1 (NF1)	Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tablet	SpringWorks Therapeutics, Inc.	NULL	Recruiting	2 Years	N/A	All	100	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03962543
(ClinicalTrials.gov)

September 6, 2019

12/4/2019

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity

Plexiform Neurofibroma;Neurofibromatosis Type 1 (NF1)

Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tablet

SpringWorks Therapeutics, Inc.

NULL

Recruiting

2 Years

N/A

All

100

Phase 2

United States